MRC/Yabao Link Indicates Growing China Capabilities
This article was originally published in PharmAsia News
The decision by MRC Technology, a UK-based independent medical research charity, to link with China's Yabao Pharmaceutical to develop and commercialize novel drugs against a neurodegenerative disorder target indicates the growing capabilities and attractions of such Chinese partners.
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.